@article{JTD22547,
author = {Chih-Cheng Hsieh and Han-Shui Hsu and Anna Fen-Yau Li and Yann-Jang Chen},
title = {Clinical relevance of PD-L1 and PD-L2 overexpression in patients with esophageal squamous cell carcinoma},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {7},
year = {2018},
keywords = {},
abstract = {Background: Even with the advance of diagnosis and the treatment, the 5-year survival rate for esophageal cancer patients is still poor. The checkpoint protein inhibition provides another choice to improve the survival. The expression of the programmed death ligand-1 (PD-L1) was reported but the clinical relevance remained inconsistent in esophageal cancer. Besides, there were few references about the other ligand, programed death ligand-2 (PD-L2). In this study, we evaluated the expressions of PD-L1 and PD-L2 in patients with esophageal squamous cell carcinoma (ESCC) and assessed their clinical relevance.
Methods: From 1996 to 2011, 150 patients undergone complete surgical resection for ESCC were enrolled. Clinical data were recorded. Expression of PD-L1 and PD-L2 on cytoplasm in paraffin embedded tumor samples were analyzed by immunohistochemistry staining and scored with a semi-quantitative method.
Results: Of the patients, 96 (64.0%) patients had PD-L1 overexpression and 63 (42.0%) had PD-L2 overexpression. There was a correlation between the expression of PD-L1 and PD-L2 (P},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/22547}
}